Funding for this research was provided by:
Agency for Healthcare Research and Quality (K12HS023011)
Dermatology Foundation (n/a)
Article History
Received: 26 July 2018
Accepted: 29 October 2018
First Online: 13 November 2018
Ethics approval
: This study was deemed exempt by the institutional review board at Northwestern University.
: Not applicable – study deemed exempt by institutional review board at Northwestern University.
: Dr. Ardalan has had travel costs for participation in a biomarker workshop reimbursed on one occasion by ReveraGen BioPharma in an amount less than $600. The authors declare that they have no other competing interests to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.